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Ever since Pauli' first recommended thiocyanates for the treat-
ment of hypertension almost forty years ago, the therapeutic value
of these drugs has been a subject of controversy. Interest appar-
ently declined after Ayman's pronouncement,' in 1931, that thio-
cyanates lacked dinical usefulness because there appeared to be an
insufficient margin of safety between the hypotensive and the toxic
doses. Recently Barker2 applied a method for the determination of
cyanates in blood and again revived interest in the thiocyanates by
claiming that their effective therapeutic range lay in a blood serum
content of from 8 to 12 mg. per cent of thiocyanate, while intoxica-
tion was not encountered until a serum level of 15 to 30 mg. had
been reached. By means of this improved control over the adminis-
tration of the drug, Barker avoided the hazards of intoxication and
achieved gratifying symptomatic results and significant amelioration
of hypertension in the majority of his patients.
The present study wasstimulated by Barker's encouragingexper-
ience with his controlled method of treatment in a disease which has
long eluded our therapeutic efforts.
Methods and frocedure
Twenty patientst with pronounced arterial hypertension were taken at
random from the wards and out-patient clinics of the New Haven Hospital
and Dispensary. Although all of the individuals included in this study were
known to have had hypertension for from one to ten years, nevertheless, a
placebo of syrup of sarsaparilla or syrup of wild cherry was administered for
several weeks or months while one of us obtained additional control blood-
pressure readings and carried out other preliminary procedures. Each case
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study included a detailed anamnesis, general physical examination, descrip-
tion of the fundus oculi, roentgenographic studies of the heart, electrocardio-
grams, urinalyses, and determinations of the non-protein nitrogen of the
blood. Pyelographic examinations were made when indicated, and early in
the study the lability of the blood pressure in some of the patients was investi-
gated by testing the response of the blood pressure to cold,4 to successive half-
hourly doses of sodium nitrite in 0.03 gm. doses, and occasionally by observing
the hourly blood-pressure course throughout a 12- to 24-hour period.
The patients were usually given one teaspoonful of a 4 per cent solution
of potassium thiocyanate in syrup of sarsaparilla three times daily by mouth.
This was equivalent to a daily dose of 0.5 gm. of the drug, and was continued
until the concentration of serum thiocyanate was found to be at the presumed
optimum level of 8 to 12 mg. per cent as suggested by Barker.2 Mainte-
nance doses were thereafter adjusted as indicated by subsequent blood analyses.
In a few patients who were under daily observation much larger initial
doses were given in order to bring the serum thiocyanate level to the desired
range more quickly. This procedure was found feasible by applying the fol-
lowing calculation of dose, which is based upon the observation that thiocy-
anate is distributed through approximately 20 per cent of the body weight:5
(1) Weight of patient x 0.2 = volume through which SCN is to be
distributed.
(2) Volume in kg. x 10 x desired SCN concentration = required total
dose in terms of SCN.
(3) SCN dose x 98/58 = required total dose of KSCN (to be given in
24 to 38 hours).
For the serum thiocyanate determinations, the micro-method of Griffith
and Lindauer,3 utilizing capillary blood, was first tried, but the results in our
hands were technically unsatisfactory. Determinations were, therefore, made
on serum from venous blood (drawn under oil) by Barker's modification of
Schreiber's technic.'
Periods of thiocyanate and placebo medication, usually of several months'
duration, were alternated without the patient's knowledge of any change in
therapy. This was facilitated by using either a 50 per cent syrup of sarsa-
parilla or syrup of wild cherry both as a placebo and as a vehicle whose exces-
sive sweetness masked the taste of the thiocyanate when the drug was added.
Patients were asked to present themselves for follow-up examinations at inter-
vals varying from one to four weeks, and at each visit a history of symptoms
was recorded and the blood pressure was determined in the sitting position
repeatedly at about five-minute intervals for at least half an hour or longer
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until several similar successive readings had been obtained. Each individual
was usually seen by the same physician throughout the period of the experi-
ment, and the blood-pressure readings were not divulged to the patient.
Except for the administration of the potassium thiocyanate and its vehide, no
other treatment or advice was given, and the patients were permitted to follow
their customary mode of living. It was sought in this way to eliminate as
far as possible the influence of psychic and extraneous factors on the blood
pressure.
Results
We believe that the evaluation of any form of treatment for
hypertension should be based primarily on a careful study of the
effect of the therapy on the blood pressure, and these data, if
published, should be offered in sufficient detail to permit an inde-
pendent appraisal by the reader. Ideally, this requires the presen-
tation of all the recorded blood-pressure readings on every patient
during the entire period of the experiment. Symptomatic effects
are admittedly both relevant and important observations, but they
lack the objectivity and freedom from suggestion that characterize
sphygmomanometric readings when the latter are- adequately
observed.
Our results, therefore, are evaluated chiefly from detailed obser-
vations of the effects of thiocyanate therapy on the patient's blood
pressures, with supplementary observations of symptomatic results,
together with briefcomments on dosage, toxicology, and a considera-
tion of possible criteria for the selection of cases suitable for
treatment.
Effect on blood pressure: It was a common observation that on
any one visit the patient's blood pressure usually declined progres-
sively as several sphygmomanometric readings were made at about
five-minute intervals. Neither maximum, minimum, nor average
blood-pressure values seemed properly to depict the blood-pressure
course; we therefore adopted the chart form illustrated in Figs. I to
14, in which the upper and lower bands represent the range of the
systolic and diastolic pressures respectively for each of the six or
more readings usually recorded at each visit.
In four patients, as is evident from Figs. 1 to 4, the blood pres-
sure dedined to normal during thiocyanate medication, and rose
again when the drug was withheld.
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FIGS. 1 to 4. Blood-pressure course in the 4
patients who responded best to thiocyanate treat-
ment. Upper and lower bands represent the range
of systolic and diastolic pressures respectively for
six or more readings at each visit. Shaded zones
indicate periods of thiocyanate medication; begin-
ning and end do not necessarily correspond with
the periods during which the serum SCN levels
were in the desired range of 8 to 12 mg. %. Hori-
zontal lines are drawn at the sphygmomanometric
leve[s of 145 and 90. Ini-
tials identify the same indi-
j Y viduals in Tables 1 to 7.
Cross-marks indicate that
these blood pressures were
:77 taken by someone other
than the authors.
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FIGs. 0 to 10. Blood-
pressure course in6patients
who responded fairly satis-
factorily.
In six patients (illustrated by Figs. 5 to 10) a relatively severe
hypertension seemed significantly ameliorated but not completely
alleviated during periods of thiocyanate administration; again, the
blood-pressure levels ascended when effective medication was
stopped.
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FIGS. 11 to 14.
Blood - pressure
course in 4 patients
whose response was
doubtful or incon-
clusive.
In four patients (see Figs. 11 to 14) the blood-pressure levels
varied considerably, but the relation to thiocyanate medication was
not dear. Further observation may lead to more certain appraisal
of these experiments.
In six patients, not illustrated, there was no apparent alteration
of the blood-pressure levels during periods of adequate thiocyanate
medication (as judged by serum SCN content) when viewed against
proper control periods of observation.
In summary, halfthe patients appeared to respond to thiocyanate
medicationwith acomplete orpartial remission of theirhypertension.
Effect on symptoms: Physicians sometimes justify the thio-
cyanates by claiming that their administration may relieve symptoms
even in the absence of any appreciable hypotensive effect. Because
of the uncertainty of subjective results as a measure of therapeutic
success, and because patients with hypertension appear especially
susceptible to suggestion, we deliberately relegated symptomatic
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data to a position of secondary importance in estimating the clinical
effects of the drug. Nevertheless, symptom notes were recorded at
every visit. In the interest of completeness these supplementary
observations are offered in the following table, which lists the symp-
tomatic results for each patient in columns that represent the general
effect of the treatment on the blood pressure.
TABLE 1
RELATION BETWEEN ALLEVIATION OF HYPERTENSION AND SYMPTOMATIC EFFECTS
Complete Partial Doubtful No
remission remission remission remission
Pt. Symptoms Pt. Symptoms Pt. Symptoms Pt. Symptoms
M. F. ? Improved J. W. Unchanged A. K. Improved D. No symptoms
H. G. Improved E. D. Unchanged M. Y. Unchanged C. K. Unchanged
J. G. Improved E. H. No symptoms A. M. Improved C. L. Unchanged
0. S. ? Improved C. B. ? Worse F. L. Worse C. R. Nosymptoms
A. H. Unchanged P. T. Nosymptoms
A. W. ? Improved H. I. ? Improved
Four patients had no symptoms before, during, or after treat-
ment. Eight patients probably felt improved during thiocyanate
therapy, yet in four ofthese the hypertension was not overcome. In
eight patients symptoms werenot relieved, although in three ofthem
the blood pressure fell appreciably but not to normal. Two of these
patients felt worse; it is noteworthy that they were not subjects
whose blood pressure had been markedly reduced. Several other
patients also felt worse during part of the thiocyanate course, but, as
will be indicated below, the increased symptoms coincided with
excessive serum thiocyanate concentrations and are probably to be
regarded as manifestations of intoxication.
It appears that symptomatic improvement is frequent but not the
rule under thiocyanate therapy and the probability of improvement
is greater if the blood pressure falls. It may occur in the absence of
a hypotensive effect, and that some patients may feel worse even if
theblood pressure has not been greatly altered. There is no evidence
in these observations to support the view held by some that hyper-
tensive patients feel less well if the blood pressure is lowered. Nor,
incidentally, did we encounter any objective evidence of injury from
the treatment, as indicated by the renal or cardiac functional status,
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eye grounds, and electrocardiograms in those patients whose hyper-
tension was appreciably diminished.
Dosage requirements: Although the "cyanating dose" could be
calculated with relative accuracy when it was desired to bring the
serum thiocyanate level quickly to a predetermined point (see
Methods and procedure), the selection of continued doses to main-
tain this serum thiocyanate concentration proved to be a highly indi-
vidual matter and usually required periodic readjustments of dose
under the guidance of frequently repeated blood analyses during the
first few weeks of the treatment. The average daily maintenance
dose for the entire group of 20 patients approximated 0.5 gm. of
potassiumthiocyanate (3 teaspoonsful daily of a 4 per cent solution),
but individual needs varied from 0.16 gm. to 0.64 gm. In general,
patients with evidence of impaired renal function could be main-
tained at a given serum thiocyanate level with smaller daily doses
than could patients with apparently normal renal function, but there
may well be other contributing factors.
Inspection of Figs. 1 to 10 reveals that significant hypotensive
effects, in the patients showing complete or partial alleviation of
their hypertension, were observed occasionally at serum SCN levels
aslowas 4-and 6 mg. percent, but that the optimal effects were most
commonly associated with serum SCN concentrations of from 8 to
15 mg. per cent.
It has long been common practice, as in our out-patient dinic, to
administer the thiocyanate salts in conventional doses of about 0.3
gmi. daily without an initial large "cyanating dose" and without con-
trol by blood analyses. We inquired briefly into the soundness of
this procedure by choosing at random from the out-patient clinic ten
patients who had been receivingthe customary daily dose of 0.3 gm.
of potassium thiocyanate for many weeks or several months. Blood
analyses in seven patients revealed serum thiocyanate levels ranging
from 1.9 to 3.5 mg. per cent; in three patients, all with evidence of
renal functional impairment, theserum thiocyanate concentration was
12.4, 17.3, and 18.7 mg. per cent.
These observations indicate the importance of evaluating the
patient's renal function before instituting thiocyanate therapy, and
illustrate the necessity for determining the serum thiocyanate levels
in regulating dosage if, on the one hand, an effective concentration
of the drug is to be achieved and, on the other, hazardous cumula-
tion is to be avoided.
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Toxic effects: The manifestations that have been attributed to
intoxication with thiocyanate salts are numerous and include, among
others, such symptoms as lassitude, anorexia, nausea, vertigo, and
weakness-symptoms which were common among our hypertensive
patients in the absence of thiocyanate medication. We therefore
regarded as probable evidence of intoxication only those symptoms
which appeared for the first time in a given patient while thiocyanate
was being administered and not dearly explained on another basis.
Judged in this broad manner, the following probably toxic effects
were encountered: macular eruption with pruritis localized to back,
once; anemia (perhaps the result of bleeding hemorrhoids), once;
nausea, three times; diarrhea, twice; marked ulnar palsy, once; pain
in jaws and teeth, twice; symptoms of upper respiratory infection,
three times; pronounced lassitude and drowsiness, four times.
These presumably toxic manifestations were all associated with
serum thiocyanate concentrations ranging between 15.7 and 21 mg.
per cent, with the following striking exception:
Patient F. L. developed pain in the jaws and sensitiveness of the teeth
to heat and cold after having taken potassium thiocyanate in a daily dose of
0.6 gm. for 14 days, at which time the concentration of the drug in the
serum was but 6.6 mg. per cent. After two more weeks of continued treat-
ment with the same dose, nausea and bloody diarrhea appeared. He did not
present himself for examination at this time but discontinued his medication
and subsequently recovered. Because we were not convinced that his symp-
toms were due to thiocyanate, and since it seemed important to establish
definitely whether intoxication might occur on a relatively low serum thio-
cyanate level, we cautiously resumed therapy two months later. At the end
of one week the pain in the jaws and temperature sensitivity of the teeth
returned, together with nausea and lassitude; the serum thiocyanate level was
6.2 mg. per cent. We believe, therefore, that these symptoms were mani-
festations of intoxication at blood thiocyanate levels that are ordinarily con-
sidered non-toxic.2 Idiosyncrasy to thiocyanate may, of course, have been
responsible.
The symptoms of pain in the jaws and temperature sensitivity
of the teeth were encountered twice in this patient and in one other
patient during thiocyanate medication. In the latter subject there
was an associated severe ulnar palsy which disappeared promptly on
the cessation of the medication and the simultaneous liberal adminis-
tration of thiamin chloride parenterally; the patient's diet had
appeared adequate and he was not an alcoholic. In the literature
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dealing with thiocyanate intoxication in man we have encountered no
previous mention of these presumably neuritic manifestations.
Although, as indicated above, intoxication was common when the
serumthiocyanate exceeded 15 mg. percent, and apparently occurred
on one occasion at a much lowerlevel, therewere numerous instances
in which no untoward effects appeared in patients whose serum thio-
cyanate concentrations inadvertently rose on occasion to values
ranging from 15 to 33 mg. per cent.
Criteria for the selection of patients
Our group of 20 subjects is admittedly too small to yield criteria
for the prediction of results unless the degree of correlation in one
feature or another proves unusually high.
Age: The patients in this study ranged from 27 to 63 years in
age. Theage distribution, when grouped according to the degree of
remission of the hypertension under thiocyanate therapy, was as
follows:
TABLE 2
RELATION OF AGE TO ALLEVIATION OF HYPERTENSION
Complete Partial Doubtful No
remssion remission remission remission
Pt. Age Pt. Age Pt. Age Pt. Age
O.S. 38 A.H. 42 A. M. 27 H. 1. 39
M.F. 45 E.D. 49 A.K. 39 C.R. 49
J.G. 45 E.H. 49 M.Y. 53 C.L. 50
H.G. 46 C.B. 50 F.L. 56 C.D. 55
A.W. 51 C. K. 57
J.W. 51 P.T. 63
Average
age 43.5 48.7 43.7 52.1
The most successfully treated group was also the youngest in
average age, while the group of therapeutic failures was the oldest,
butequallyyoung individuals occurred at both extremes and the cor-
relation of age with type of response was not uniform through the
four groups. Relative youth was not, therefore, a guarantee of suc-
cess, for only one of four patients below the age of 40 responded
well.
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Sex: The 20 subjects induded 13 females and 7 males. The
sex distribution of the patients, when grouped according to the
degree of therapeutic remission of the hypertension, was as follows:
TABLE 3
RELATION OF SEX TO ALLEVIATION OF HYPERTENSION
Complete Partial Doubtful No
remission remission remission remission
Males 3 1 1 2
Females 1 5 3 4
Evidently both sexes responded in about equal proportions.
Duration of hypertension: If it is held that structural changes
in the arterioles advance with increasing duration of hypertension,
one might anticipate best therapeutic results in patients whose disease
is still ofrelatively recent development. Examination of our results
from this point of view revealed the following relationship between
the known duration of hypertension and the therapeutic response:
TABLE 4
RELATION OF DURATION OF HYPERTENSION TO ITIS THERAPEUTIC ALLEVIATION
Commpete Partiil Doubtful No
remssin remission remission remissi
Pt. Duration Pt. Duration Pt. Duration Pt. Duration
yrs. yrs. yrs. yrs.
H.G. 2 A.W. 1 A.M. I P.T. 2
O.S. 3.5 A. H. 1.5 F.L. 1.5 C.D. 4
M.F. 5 J.W. 3 M.Y. 3.5 C.K. 5
J.G. 7 E.H. 5 A.K. 8 H.I. 5
C.B. 6 C.R. 8
E.D. 10+
Average
duration 4.2yrs. 4.4+yrs. 3.5yrs. 4.2yrs.
Whilethere maybe a considerable difference between the known
and the actual duration of hypertension, a similar error would prob-
ably appear in all four groups. Successes and failures with thio-
cyanate therapy were encountered in patients whose hypertension
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was presumably of recent onset as well as in those who were known
to have had the disease for many years. The duration of the hyper-
tension seemed, therefore, to have no definite bearing on the results
of the treatment.
Severity of hypertension: For the convenience of this discussion
each patient's hypertension has been roughly classified as follows:
+ =mild hypertension, with blood pressures usually not exceeding
175/100.
++ =moderate hypertension, with blood pressures usually not exceed-
ing 200/110.
+++ =severe hypertension, with blood pressures usually exceeding
200/110.
In Table 5, which follows, the relation of the grades of hyper-
tension to the varieties of therapeutic response to thiocyanate is
shown.
TABLE 5
RELATION OF GRADE OF HYPERTENSION TO ITS THERAPEUTIC ALLEVIATION
Complete Partia Doubtfud No
remiussion remission remission reision
Pt. Grade Pt. Grade Pt. Grade Pt. Grade
M.F. 4+ A.H. -- M.Y. + C.R. 4+
H.G. 4+ J.W. 4+ A.M. -H- P.T. -H
J.G. 1 E. E.D. 1- A.-K. +-i C.D.
O.S. 11H E.H. 111 F.L. 1--H C.K. 11
A.W. 111 C.L. 11H
C. B. I- H.I. -I-II
The proportion of patients with moderate and severe hyperten-
sion was practically the same in the two groups showing a thera-
peutic response as in the two groups that did not. Apparently the
presence of severe hypertension is not inimical to a satisfactory thera-
peutic remission. It is possible that patients with mild hypertension
might have responded more uniformly with a complete remission of
the hypertension, but our cases included only one in this classification
and the results in this individual were not conclusive.
The presemwe of compllications: Although we excluded from
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this study patients with advanced cardiac and renal failure, the
majority of our subjects gave some evidence of disease of the heart
or kidneys. The approximate degree to which such complications
were present ineach group is indicated in Table 6. (A renal lesion of
grade "+" means moderate albuminuria without hyposthenuria or
nitrogen retention; grade "++" means hyposthenuria and nitrogen
retention without terminal nephritis. A cardiac lesion of grade "+"
means cardiac enlargement, with deviation of electrical axis to left,
and no functional limitations without digitalis; grade "++"
indudes functional impairment requiring digitalis, abnormal T
direction or QRS duration in electrocardiograms.)
TABLE 6
RELATION OF RENAL' AND CARDIAC COMPLICATIONS TO ALLEVIATION OF
HYPERTENSION
Compele Partia Doubtful No
rems;son remission remission remUsson
'I
H. G. 0 + J. W. 0 + A. K. 0 ++ C. L. + ++
M. F. 0* H E. D. 0 4+ M. Y. 0 + C.D. 0 4+
J. G. + *± E. H. 0 4+ A. M. 0 + C. K. ++ ++
O. S. ±+ + C. B. 0 +* F. L. 0 4+ C. R. 0 4+
A.W. 4+ 4+ P.T. 0 4+
A.H. 0 + H. 1 0 | +
* Nephrectomy for hydronephrosis one year before.
** Congenital heart disease.
It is apparent from Table 6 that renal and cardiac complications
were present in the successfully treated patients to about the same
extent as in those that failed to respond. The presence of these
complications does not, therefore, predude successful treatment of
hypertension with thiocyanates.
Retigitisinrelationtoresponse: Noneof ourpatients had exten-
sive sclerosis or calcification of the peripheral arteries that were
palpable. As an indication of vascular disease the eye grounds were
examined and graded from "O" to "++++" in the direction of
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increasing hypertensive retinitis. Since the severity of hypertensive
disease is, in a sense, an expression of the extent of arteriolar abnor-
malities, it seemed interesting to compare the varieties of therapeutic
response with the degree of associated retinitis in each group. This
was done in Table 7, which follows:
TABLE .7
RELATION OF RETINITIS TO ALLEVIATION OF HYPERTENSION
Complete Partiad DoubtfuS No
remission reCmision remission re6msson
Pt. Retinitis Pt. Retinitis Pt. Retinitis Pt. Retinitis
H.G. 0 A.H. 0 A.M. 0 C.D. +
J.G. + C.B. + F.L. + C.R. +
O.S. w A.W. + A.K. + P.T. +
M.F. + E.H. SF4 M.Y. + H.I. +
E.w. D -H. C.K. 4+
J.W. 111 C.L. St
There is no apparent correlation between the degree of retinitis
and the blood-pressure response to thiocyanate. The fact that the
group with the least abnormality showed only doubtful effect of the
treatment on blood pressure is probably insignificant.
Cold pressor and txstrite tests: In ten patients an attempt was
made to ascertain their vasomotor reactivity with the purpose of
determining whether the positive demonstration of induced lability
of the blood pressure would coincide with a favorable therapeutic
response to thiocyanates and might serve, therefore, as a basis for
the selection of cases. For this purpose the cold pressor test as
described by Hines and Brown4 was used. This was usually supple-
mented by a "nitrite test," which consisted in the oral administration
of 0.03 gm. of sodium nitrite every half hour until an appreciable
lowering of blood pressure was manifested or until a maximum of
sixdoses had been given. In a few patients the lability ofthe hyper-
tension was studied by obtaining an hourly blood-pressure reading
through a 24-hour period. No correlation was obvious between
blood-pressure changes with these procedures and success or failure
to respond to thiocyanate therapy.
We failed, therefore, to find any obvious clue which might prove
helpful in predicting a favorable response to treatment. The data
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are, nevertheless, presented in the hope that they may contribute
toward the accumulation of more abundant and adequate informa-
tion from which criteria for the selection of patients may ultimately
evolve.
Summary
Of 20 patients who were treated with potassium thiocyanate in
large "controlled" doses, 10 manifested significant lowering of the
blood pressure, with complete remission of hypertension in four.
Symptomatic improvement was about equally common but was
not necessarily associated with relief from hypertension.
Optimalbeneficialeffects onbloodpressurewere most commonly
noted when the serum SCN concentration ranged from 8 to 15 mg.
per cent.
Toxic manifestations were common with serum SCN concentra-
tions above 15 mg. per cent, but were not invariably present even
with twice this concentration; on the other hand, serious intoxication
was encountered with serum SCN concentrations of between 6 and 7
mg. per cent in one patient.
A rapid method of bringing the serum SCN concentration to any
desired level is described. The estimation of maintenance doses of
potassium thiocyanate proved to be a highly individual matter and
required frequent quantitative determinations of serum SCN.
Toxic manifestations not generally attributed to thiocyanate
included pain in the jaws, temperature sensitivity of the teeth, and
ulnar palsy; these may all represent expressions of peripheral
neuritis.
Examination of our data for criteria that might serve for the.
selection of patients suitable for this form of therapy included con-
siderations of age, sex, duration of hypertension, severity of hyper-
tension, cardiacand renal complications, retinitis, andtests ofvascular
reactivity; none showed a sufficiently high correlation to appear
useful.
Conclusion
Remission of hypertension and symptoms may be induced in
some patients by the oral administration of potassium thiocyanate in
relatively large doses, but the proper control of dosage requires
repeated observations of the serum SCN concentrations.
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